Eli Lilly’s Zepbound (tirzepatide) delivered 20.2% average body weight reduction in the SURMOUNT-5 head-to-head trial, compared to 13.7% for Novo Nordisk’s Wegovy (semaglutide 2.4 mg). The FDA approved Wegovy for chronic weight management in June 2021, and Zepbound followed in November 2023.
Both medications are once-weekly subcutaneous injections, but Zepbound activates two hormone receptors (GIP and GLP-1) while Wegovy targets only GLP-1. In the 72-week SURMOUNT-5 study published in 2025, 31.6% of Zepbound patients achieved 25% total body weight loss, compared with 16.1% on Wegovy.
The SURMOUNT-1 trial enrolled 2,539 adults with obesity and showed that Zepbound’s highest dose (15 mg) produced an average body weight loss of 22.5% over 72 weeks. Wegovy’s pivotal STEP-1 trial enrolled 1,961 participants and documented an average weight loss of 14.9% at 68 weeks.
Both drugs carry a black box warning for thyroid C-cell tumors based on rodent studies, and both require gradual dose escalation over 16 to 20 weeks to reduce gastrointestinal side effects. Patients typically notice appetite suppression within 4 to 8 weeks, though maximum weight loss continues through month 18. The similar side effect profiles should help patients feel more comfortable with either option.
This guide compares Zepbound and Wegovy across mechanism of action, clinical trial outcomes, side effect profiles, dosing schedules, cost, insurance coverage, and real-world results, helping patients evaluate affordability and access.
At Green Relief Health in Baltimore, Dr. Lauren Nawrocki and her team prescribe medications as part of a comprehensive medical weight-loss program after a full metabolic evaluation. The right choice depends on your starting BMI, medical history, insurance formulary, and response to initial dosing, emphasizing personalized care.
44%
Patients report nausea
22.5%
Avg body weight lost
4-8 wks
When effects peak
6
Available doses
Considering Zepbound or Wegovy?
Our medical team can help you compare your options, review your health history, and build a personalized medical weight-loss plan.
✨ What You’ll Learn
- How Zepbound and Wegovy Work Differently
- Zepbound’s Dual-Action Mechanism
- Wegovy’s GLP-1 Only Approach
- Clinical Trial Results: SURMOUNT and STEP Data
- Side Effect Profiles Compared
- Dosing Schedules and Titration
- Cost, Insurance, and Access
- Choosing Between Zepbound and Wegovy
- Final Thoughts
- Frequently Asked Questions
How Zepbound and Wegovy Work Differently
Zepbound and Wegovy belong to the same drug class (incretin mimetics) but act on different receptors. Tirzepatide, the active ingredient in Zepbound, binds two gut hormone receptors simultaneously. Semaglutide, the active ingredient in Wegovy, binds to only one. This mechanistic difference explains the larger weight loss seen in Zepbound trials.
Zepbound’s Dual-Action Mechanism
Zepbound activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. GIP suppresses appetite, improves insulin sensitivity, and reduces food intake. GLP-1 slows gastric emptying, increases satiety, and lowers blood sugar. Activating both receptors produces a synergistic effect on appetite and metabolism. Dr. Ania Jastreboff and colleagues reported in the New England Journal of Medicine (2022) that Zepbound reduced daily caloric intake by roughly 600 calories in SURMOUNT-1 participants.
Key Distinction: Zepbound is the only FDA-approved weight-loss medication that targets two incretin receptors simultaneously. Wegovy, Ozempic, and Saxenda all target GLP-1 alone.
Wegovy’s GLP-1 Only Approach
Wegovy delivers semaglutide at 2.4 mg weekly, which is higher than the 1.0 mg maximum used in Ozempic for type 2 diabetes. The drug slows stomach emptying, signals fullness to the hypothalamus, and reduces food cravings. Wegovy was the first once-weekly GLP-1 agonist approved specifically for chronic weight management in adults with a BMI of 30 or greater, or 27 with at least one weight-related condition like hypertension or dyslipidemia. Read our complete Wegovy guide for the full clinical background.
Clinical Trial Results: SURMOUNT and STEP Data
Head-to-head trials and pivotal studies provide the clearest evidence for comparing these two drugs. Each medication was approved based on separate Phase 3 programs, then directly compared in the SURMOUNT-5 study.
SURMOUNT-1: Zepbound’s Pivotal Trial
SURMOUNT-1 randomized 2,539 adults with obesity (mean BMI of 38) to tirzepatide 5 mg, 10 mg, 15 mg, or placebo. After 72 weeks of treatment, the 15 mg group lost an average of 22.5% of body weight, the 10 mg group lost 19.5%, and the 5 mg group lost 15.0%. The placebo arm lost only 2.4%. Roughly 36% of patients on the 15 mg dose achieved 25% or greater total body weight loss, a benchmark historically reserved for bariatric surgery outcomes.
STEP-1: Wegovy’s Pivotal Trial
STEP-1 enrolled 1,961 non-diabetic adults and assigned them to semaglutide 2.4 mg weekly or placebo. Over 68 weeks, the semaglutide group lost an average of 14.9% of body weight, compared with 2.4% for placebo. About 32% of Wegovy patients reached 20% or more weight loss, and 50.5% achieved at least 15%.
SURMOUNT-5 Head-to-Head Comparison
SURMOUNT-5 directly compared tirzepatide and semaglutide in 751 adults with obesity or overweight. At 72 weeks, tirzepatide produced an average weight loss of 20.2% versus 13.7% for semaglutide, a 47% relative advantage for Zepbound. Patients on tirzepatide lost an average of 50.3 pounds compared to 33.1 pounds for semaglutide.
| Trial Metric | Zepbound 15 mg | Wegovy 2.4 mg |
|---|---|---|
| Average weight loss (pivotal) | 22.5% | 14.9% |
| Head-to-head result (SURMOUNT-5) | 20.2% | 13.7% |
| Trial duration | 72 weeks | 68 weeks |
| Participants with 15% or more loss | 78% | 50.5% |
| Participants with 25% or more loss | 36% | 16.1% |
Clinical Note: SURMOUNT-5 results were presented at the American Diabetes Association meeting in June 2025 and confirmed Zepbound’s superiority across every measured endpoint, including waist circumference, blood pressure, and A1C reduction.
Side Effect Profiles Compared
Both medications share a similar side-effect profile because they act on overlapping receptors. Gastrointestinal complaints account for the majority of reported adverse events, and most occur during dose escalation.
Gastrointestinal Reactions
Nausea is the most common complaint with both drugs, though the exact frequency varies slightly by dose and titration speed. The following table compiles frequencies from the highest approved doses of each medication:
| Side Effect | Zepbound 15 mg | Wegovy 2.4 mg |
|---|---|---|
| Nausea | 29% | 44% |
| Diarrhea | 23% | 30% |
| Constipation | 17% | 24% |
| Vomiting | 13% | 24% |
| Abdominal pain | 10% | 20% |
| Injection site reaction | 6% | 3% |
Management: Starting with small meals, avoiding fried or greasy foods, and staying hydrated reduces nausea severity. Many patients find symptoms fade after the first 4 to 6 weeks of each dose level. IV hydration therapy can help manage dehydration during the titration phase.
Black Box Warning and Serious Adverse Events
Both Zepbound and Wegovy carry a boxed warning for medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 (MEN 2). Rodent studies showed an increased risk of thyroid C-cell tumors, though human data remain inconclusive. Patients with a personal or family history of these conditions cannot take either drug. Pancreatitis, gallbladder disease, and acute kidney injury have also been reported with both medications.
⚠️ Black Box Warning
Do not use Zepbound or Wegovy if you or a family member has medullary thyroid carcinoma or MEN 2. Stop the medication and seek immediate care if you develop severe abdominal pain, which could indicate pancreatitis.
Dosing Schedules and Titration
Both drugs require gradual dose escalation to minimize gastrointestinal symptoms. The target dose typically arrives after 16 to 20 weeks of incremental increases.
Zepbound Dose Escalation
Zepbound comes in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The standard schedule starts at 2.5 mg weekly for the first four weeks, then increases by 2.5 mg every four weeks until the maintenance dose. Prescribers often stop at 5 mg, 10 mg, or 15 mg based on patient response and tolerance. Read more about how Zepbound works for weight loss in our detailed breakdown, or explore our tirzepatide program to learn about candidacy and pricing.
Wegovy Dose Escalation
Wegovy offers five doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. The titration schedule moves patients from 0.25 mg to 2.4 mg over 16 weeks, with each dose lasting four weeks. Unlike Zepbound, Wegovy has only one maintenance target at 2.4 mg, though some patients remain on 1.7 mg if they cannot tolerate the higher dose.
Cost, Insurance, and Access
Price and coverage often drive the final prescription decision, especially for patients paying out of pocket or facing insurance denials.
List Price Comparison
As of early 2026, Zepbound’s cash price runs approximately $1,086 per month for any dose, while Wegovy lists at roughly $1,349 per month. Eli Lilly launched a vial program offering Zepbound single-dose vials at $349 for 2.5 mg and $499 for 5 mg, making it the cheaper option for self-pay patients. Novo Nordisk has not released a similar vial discount program.
Insurance Coverage Differences
Commercial insurance coverage varies widely. Some employer plans cover Wegovy but not Zepbound; others cover both; and many exclude weight-loss drugs entirely. Medicare does not cover either obesity medication, though Part D plans may cover Wegovy for cardiovascular risk reduction following its March 2024 approval for that indication.
Prevention Strategy
Before starting either drug, request a prior authorization check through your insurance carrier. Many denials can be overturned with documentation of BMI, comorbidities, and failed lifestyle attempts.
Choosing Between Zepbound and Wegovy
No single answer fits every patient. The decision depends on medical history, treatment goals, insurance, and personal preferences.
When Zepbound May Be the Better Choice
Patients seeking maximum weight loss, those with type 2 diabetes, and individuals who previously tried GLP-1 only drugs without success often respond better to Zepbound’s dual-receptor action. The drug also offers greater dose flexibility with six strengths, helping providers fine-tune their response over time.
When Wegovy May Be the Better Choice
Wegovy may fit patients with established cardiovascular disease because the FDA approved it in March 2024 to reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and existing heart disease. Zepbound does not yet carry this indication. Patients whose insurance only covers semaglutide-based drugs also benefit from choosing Wegovy. For deeper comparisons across the GLP-1 category, see our Wegovy vs Mounjaro and Wegovy vs Ozempic guides.
Book a Consultation
Speak with Green Relief Health about your medical history, insurance access, and weight-loss goals.
Final Thoughts
Zepbound and Wegovy are the two most effective FDA-approved weight-loss medications on the market in 2026. Zepbound delivers greater average weight loss across both SURMOUNT-1 and SURMOUNT-5 head-to-head studies, with patients losing roughly 22.5% of body weight at the 15 mg dose, compared to 14.9% with Wegovy. The difference reflects tirzepatide’s dual-receptor mechanism, which simultaneously activates both the GIP and GLP-1 pathways.
Wegovy remains a strong option for patients with cardiovascular disease, those who respond well to GLP-1 only therapy, or individuals whose insurance formulary favors semaglutide. Both drugs share similar gastrointestinal side effects, carry identical black box warnings, and require the same gradual dose titration. The right choice depends on your specific medical history, BMI, and treatment response.
At Green Relief Health in Baltimore, Dr. Lauren Nawrocki evaluates every weight-loss candidate with a comprehensive metabolic panel, medical history review, and a personalized dosing plan. Our team prescribes both Zepbound and Wegovy, along with nutritional guidance and hormone optimization therapy when indicated. Patients who experience facial volume loss during significant weight reduction may benefit from complementary treatments such as dermal fillers or Kybella injections for submental contouring.
Frequently Asked Questions
Is Zepbound more effective than Wegovy for weight loss?
Yes, Zepbound produced greater weight loss in the SURMOUNT-5 head-to-head trial. Patients on tirzepatide lost 20.2% of body weight over 72 weeks compared to 13.7% on semaglutide. Zepbound’s 15 mg dose also produced 22.5% average loss in SURMOUNT-1, the highest weight loss ever recorded in a major weight management drug trial. The difference comes from tirzepatide activating both GIP and GLP-1 receptors while semaglutide targets only GLP-1.
Can I switch from Wegovy to Zepbound?
Yes, switching is possible and commonly done when the Wegovy response plateaus. Most providers start Zepbound at the 2.5 mg starter dose one week after the last Wegovy injection, even if the patient was on a higher Wegovy dose. The titration schedule restarts to allow the body to adjust to tirzepatide’s different receptor profile. Discuss timing with your provider to avoid overlap or gaps in appetite suppression.
Which drug has fewer side effects?
Zepbound produces slightly lower rates of nausea, vomiting, and constipation at its highest dose compared to Wegovy. In trial data, 29% of Zepbound users reported nausea versus 44% for Wegovy, though individual responses vary widely. Both drugs cause similar rates of gallbladder issues and pancreatitis. Slow titration and dietary adjustments reduce symptoms for most patients on either medication.
How long do I need to stay on Zepbound or Wegovy?
Both medications are designed for long-term use, and stopping leads to weight regain in most patients. The STEP-1 extension trial showed that participants regained about two-thirds of the weight they had lost within a year of stopping Wegovy. SURMOUNT-4 documented similar regain patterns after discontinuing Zepbound. Most obesity specialists consider these drugs to be chronic therapy similar to blood pressure or cholesterol medications.
What does Zepbound or Wegovy cost without insurance?
Zepbound’s list price runs about $1,086 per month, while Wegovy costs roughly $1,349 per month. Eli Lilly offers Zepbound vials at $349 to $499 per month for self-pay patients, which reduces out-of-pocket costs substantially. Manufacturer savings cards can reduce commercial insurance copays to as low as $25 per month for eligible patients. Call (410) 368-0420 to verify coverage options through the clinic’s verification process.
Do Zepbound and Wegovy help with conditions beyond weight loss?
Both drugs improve blood sugar, blood pressure, cholesterol, and the severity of obstructive sleep apnea. Zepbound received FDA approval in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity based on the SURMOUNT-OSA trial. Wegovy received cardiovascular risk reduction approval in March 2024 for patients with established heart disease. Both medications reduce A1C by roughly 2 percentage points in patients with type 2 diabetes.
Can I use Zepbound or Wegovy with other weight loss treatments?
Yes, both medications pair well with nutritional counseling, exercise programs, and medical spa treatments. Patients who lose significant weight sometimes experience loose skin or changes in facial volume and benefit from volume restoration treatments. Combining GLP-1 therapy with hormone optimization can also address weight loss resistance in perimenopausal women and men with low testosterone.
How soon will I see results on either medication?
Most patients notice appetite suppression within the first 2 to 4 weeks and visible weight loss by week 8. Maximum effect typically occurs between months 12 and 18, as patients reach their target dose and sustain momentum in weight loss. The average Zepbound patient loses about 1.5 pounds per week during active titration, while Wegovy users average 1 pound per week. Results vary based on starting weight, diet adherence, and physical activity level.
Ready to Compare Zepbound and Wegovy?
Get a personalized medical weight-loss plan with dose guidance, insurance support, and ongoing monitoring from the Green Relief Health team in Baltimore.
📍 7690 Belair Road, Suite 1, Baltimore, MD 21236 | 📞 410-368-0420
↑
